The WORKER Study: Escitalopram and Telephone-based Cognitive Behaviour Therapy (CBT) for Depressed Working People
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00702598|
Recruitment Status : Completed
First Posted : June 20, 2008
Last Update Posted : May 9, 2012
|Condition or disease||Intervention/treatment||Phase|
|Major Depressive Disorder (MDD)||Behavioral: Telephone-based Cognitive Behaviour Therapy (CBT) Behavioral: Telephone reminder calls||Not Applicable|
Rationale CBT is recognized as an effective psychological treatment for MDD. However, there are still considerable barriers to access CBT. Newer methods of delivering CBT, such as over the telephone (Tel-CBT), allow for greater access and convenience, at potentially lower cost. This is especially relevant for working people because the service can be delivered during evenings and weekends, so they do not need to leave work to attend clinic appointments. Ease of access is also important for rural settings where distance to health facilities can be a barrier to care. The ease of delivery of Tel-CBT, both in setup and maintenance costs, may also make it an important component of enhanced support for primary care. Preliminary studies have shown that addition of Tel-CBT leads to better outcomes than usual care alone (Simon et al, 2004; Wang et al, 2007).
This study will investigate the added value of Tel-CBT as adjunctive treatment to an antidepressant (escitalopram) in working people with MDD versus treatment with escitalopram alone, focusing on work-related outcomes. Escitalopram offers advantages as a first-choice treatment for depressed working people, given its superior efficacy compared to other antidepressants, excellent tolerability and simplicity of use for family physicians. Observational studies have shown significant reductions in sick leave when depressed patients are treated with escitalopram (Winkler et al, 2007). Outcome will be rigorously evaluated by assessing absenteeism and work productivity, response and remission rates, and quality of life, after acute (3 month) treatment and longer-term (6 month) follow-up.
Research Method This is a 6-month, multi-centre, single-blind (rater), randomized, parallel-design study to assess the efficacy of escitalopram and Tel-CBT in the treatment of working subjects with MDD, compared to treatment with escitalopram alone. A total of 150 depressed patients meeting entry criteria will be enrolled over a 1 year period.
Eligible patients will be treated with escitalopram 10-20 mg/d for the entire treatment period (6 months). Patients will be randomized to addition of telephone-based CBT with 8 sessions conducted over a 3 month period, or to a (placebo) control condition of reminder telephone calls. Outcomes (HAM-D, MADRS) will be primarily assessed over the telephone by raters blind to treatment assignment. Other outcome measures will be assessed by patient-rated questionnaires administered over the internet using a secure web site, and by ratings from the treating physician (CGI and adverse events).
Statistical Analysis All randomized subjects who have at least one follow-up visit will be included in the analysis based on intent-to-treat. Ineligible subjects who are inappropriately randomized will be excluded from the analysis. Missing data will be imputed using last observation carried forward (LOCF). For the analyses the treatment variables will remain coded and the analysts and investigators will remain blinded to variable identity during analysis and interpretation.
The pre-specified primary efficacy endpoint is the adjusted mean change from baseline to endpoint (12 weeks) in the HAM-D score using LOCF. All comparisons will be analyzed using ANCOVA adjusting for baseline value and centre. The secondary outcomes will also be analyzed using a similar analysis, when appropriate. Post hoc analyses will also examine observed case data. Categorical data (such as proportions of the sample with adverse events) will be analyzed using chi-square tests or Fisher's test where cell sizes warrant.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||105 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||The WORKER Study: A Randomized Controlled Trial of Escitalopram and Telephone-based Cognitive Behaviour Therapy in Working Patients With Major Depressive Disorder|
|Study Start Date :||June 2008|
|Actual Primary Completion Date :||April 2011|
|Actual Study Completion Date :||December 2011|
Telephone-based Cognitive Behaviour Therapy
Behavioral: Telephone-based Cognitive Behaviour Therapy (CBT)
Telephone-based CBT: Eight sessions of telephone-based CBT (Tel-CBT) will be delivered over 8-10 weeks, based on a published manual (Simon et al, 2004). Tel-CBT has been modified to be briefer than traditional CBT (30-40 minutes instead of 60 minutes per session) and will be offered at convenient times (including evening sessions). The initial Tel-CBT session will occur within 2 weeks of randomization, with subsequent sessions occurring every 1-2 weeks depending on scheduling and patient preference. The initial session focuses on motivation enhancement exercises, subsequent sessions emphasize identifying, challenging and distancing from negative thoughts, and the final session focuses on a personal care plan and self-management skills.
Placebo Comparator: 2
Telephone reminder calls
Behavioral: Telephone reminder calls
Telephone reminder calls: Weekly telephone calls for 8 weeks to inquire on progress and remind patients to take their medications properly
- Change in adjusted HAM-D and MADRS scores at 3 month followup [ Time Frame: 6 months ]
- At 3 and 6 month followup: clinical response and remission rates, absenteeism and work productivity, adverse events, quality of life, and cost-effectiveness. [ Time Frame: 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00702598
|Canada, British Columbia|
|UBC Hospital Mood Disorders Centre|
|Vancouver, British Columbia, Canada, V6T 2A1|
|Principal Investigator:||Raymond W. Lam, MD, FRCPC||University of British Columbia|
|Study Director:||Sagar V. Parikh||University of British Columbia|
|Study Director:||Erin E. Michalak||University of British Columbia|
|Study Director:||Kevin Solomons||University of British Columbia|
|Study Director:||Sidney H. Kennedy, Ph.D||University of British Columbia|
|Study Director:||Edwin M. Tam||University of British Columbia|